GPRC5D Is An Active Immunotherapeutic Target in Multiple Myeloma
Findings from a phase I, dose-escalation study of a second-generation CAR T-cells in patients with relapsed or refractory multiple myeloma
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1650 results
Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab Alone in Patients with Stage IIIB-D or IV Melanoma
Findings from the CheckMate 915 study primary endpoints of recurrence-free survival in the all randomised population and in patients with tumour PD-L1 expression < 1%
Fourth Vaccine Dose Increases in Humoral Immunity Against Omicron Variants in Patients with Cancer
Passive immunisation with tixagevimab and cilgavimab may not be effective
FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours
Evidence for efficacy is based on the results from the LIBRETTO-001 study
FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC
FDA also approved the Oncomine Dx Target Test as a companion diagnostic for selpercatinib
Utility of Genomic Profiling of cfDNA to Inform Clinical Care for Patients with Advanced Biliary Tract Cancer
Limitations of cfDNA for detection of FGFR2 fusions
Higher Efficacy, But Also More Toxicity of Axicabtagene Ciloleucel Compared to Tisagenlecleucel in Relapsed/Refractory DLBCL
Findings from an individual patient data based matched comparison of efficacy and safety between two commercial CAR T cell products
Clinical Utility of ctDNA NGS for Detecting Actionable Alterations According ESCAT in Patients with Advanced Cancer
Findings from the French National Center for Precision Medicine
EMA Recommends Extension of Indications for Crizotinib
Two new indications concern the treatment of paediatric patients with ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumour
EMA Recommends Granting a Conditional Marketing Authorisation for Loncastuximab Tesirine
It is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma
EMA Recommends Extension of Indications for Axicabtagene Ciloleucel
New indication concerns the treatment of patients with diffuse large cell lymphoma and high-grade B-cell lymphoma
RNF43 Mutations Warrant Further Validation for Potential to Prioritise Anti-EGFR/BRAF Combinations in Selected Patients with BRAFV600E-Mutated mCRC
Findings from an assessment of predictive value of RNF43 status in patients with BRAFV600E-mutated metastatic colorectal cancer